4DMedical Limited (ASX:4DX)
Australia · Delayed Price · Currency is AUD | Market Cap | 2.35B +1,908.8% |
| Revenue (ttm) | 5.81M -0.8% |
| Net Income | -172.93M |
| EPS | -0.41 |
| Shares Out | 592.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,042,765 |
| Open | 3.990 |
| Previous Close | 3.920 |
| Day's Range | 3.880 - 4.000 |
| 52-Week Range | 0.230 - 7.550 |
| Beta | 2.01 |
| Analysts | Hold |
| Price Target | 4.97 (+25.19%) |
| Earnings Date | Jun 10, 2026 |
About 4DMedical
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non‑invasive respiratory imaging solution using four‑dimensional imaging. It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of poten... [Read more]
Financial Performance
In fiscal year 2025, 4DMedical's revenue was 5.85 million, an increase of 55.91% compared to the previous year's 3.75 million. Losses were -30.07 million, -16.42% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for 4DX stock is "Hold." The 12-month stock price target is $4.97, which is an increase of 25.19% from the latest price.
News
4DMedical Press release: M&A announcement
4DMedical issued a press release on June 8, 2026, disclosing material business information to investors.
4DMedical Transcript: Status update
CT:VQ functional imaging enables better patient selection and monitoring for lung therapies, improving outcomes and workflow efficiency. Strong clinical interest, pharma partnerships, and a robust sales pipeline support rapid adoption, with major studies and European expansion ahead.
4DMedical Transcript: AI & Technology Virtual Investor Conference
A software-driven imaging platform is rapidly displacing nuclear VQ scans in the U.S. with a CT-based alternative, offering faster, safer, and more accessible diagnostics. Strategic partnerships and rapid adoption at top hospitals are fueling expansion, with plans to grow the addressable market and enter new regions.
4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union
In a separate announcement made today, the Company also secured A$83 million in private placement funding to support growth initiatives, including European expansion. MELBOURNE, Australia, March 30, 2...
4DMedical Quarterly report: H1 2026
4DMedical has published its H1 2026 quarterly earnings report on February 26, 2026.
4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging
Funding will scale hospital deployments for groundbreaking CT:VQ™ imaging product, strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health,...
4DMedical Transcript: Investor Update
CT:VQ, a non-invasive lung imaging software, is gaining strong traction with leading U.S. hospitals and benefits from a major partnership with Philips, including a minimum order commitment and government exclusivity. The company is well-funded, has robust IP protection, and is focused on rapid market expansion and reference customer acquisition.
4DMedical Press release: Investor Update
4DMedical issued a press release on December 3, 2025, disclosing material business information to investors.
4DMedical Earnings release: Q1 2026
4DMedical released its Q1 2026 earnings on October 29, 2025, summarizing the period's financial results.
4DMedical Annual report: H2 2025
4DMedical has published its H2 2025 annual report on September 24, 2025.
4DMedical's CT:VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology
Medicare confirms reimbursement, unlocking nationwide access to non-contrast ventilation–perfusion imaging from routine chest CT LOS ANGELES , Sept. 4, 2025 /PRNewswire/ -- 4DMedical, a leader in adva...
4DMedical Transcript: Investor Update
FDA approval for CTV-Q enables immediate U.S. rollout, targeting a $1.1 billion market with instant scalability via existing CT infrastructure. Clinical validation shows strong equivalence to nuclear VQ, with superior workflow, economics, and patient experience. Commercialization leverages direct and partner channels, with reimbursement expected this year.